← Leaderboards
Karl Y Hostetler
Veterans Medical Research Fdn/San Diego
$9,091,197
Attributed
$10,225,338
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$10,225,338 · 8
By mechanism
R01$9,654,525 · 7
R21$570,813 · 1
Top collaborators
- Robert Turner Schooley3 shared
Others in their field
Top investigators on “Prodrugs”
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Robert Turner Schooley · University Of Colorado Denver$47,231,917
- Lynn Kirkpatrick · Ensysce Biosciences, Inc.$26,039,397
- David Heimbrook · Leidos Biomedical Research, Inc.$21,781,988
- Kevin V Grimes · Stanford University$14,783,804
Research focus
ProdrugsNucleosidesAntiviral AgentsLeadMetabolicIn VitroToxic EffectDrug KineticsAnalogPharmaceutical PreparationsOralPhosphonateEvaluationCellsIn VivoLaboratory MouseCidofovirEstersLipidsAcquired Immunodeficiency SyndromeLiverDrug Design /Synthesis /ProductionInhibitor/AntagonistUptake
Grant awards (24)
Revising Anti-coronavirus Compounds to Enhance Activity and Optimize Delivery$750,972
R01 · FY2023 · AI
Revising Anti-coronavirus Compounds to Enhance Activity and Optimize Delivery$751,145
R01 · FY2022 · AI
Revising Anti-coronavirus Compounds to Enhance Activity and Optimize Delivery$766,165
R01 · FY2021 · AI
Optimization of HPMPA and CDV Analogs for Treatment of Smallpox$525,526
R01 · FY2011 · AI · contact PI
Optimization of HPMPA and CDV Analogs for Treatment of Smallpox$536,062
R01 · FY2010 · AI · contact PI
POTENT NEW NUCLEOSIDE ANALOGS FOR DRUG RESISTANT HIV$336,518
R01 · FY2010 · AI · contact PI
Optimization of HPMPA and CDV Analogs for Treatment of Smallpox$541,123
R01 · FY2009 · AI · contact PI
POTENT NEW NUCLEOSIDE ANALOGS FOR DRUG RESISTANT HIV$339,917
R01 · FY2009 · AI · contact PI
Optimization of HPMPA and CDV Analogs for Treatment of Smallpox$551,277
R01 · FY2008 · AI · contact PI
POTENT NEW NUCLEOSIDE ANALOGS FOR DRUG RESISTANT HIV$305,925
R01 · FY2008 · AI · contact PI
POTENT NEW NUCLEOSIDE ANALOGS FOR DRUG RESISTANT HIV$311,850
R01 · FY2007 · AI · contact PI
Nucleoside Phosphonate Analogs and HPV Positive Cancers$274,073
R01 · FY2007 · CA · contact PI
Nucleoside Phosphonate Analogs and HPV Positive Cancers$282,258
R01 · FY2006 · CA · contact PI
Lung-Targeted Poxivirus Antivirals$282,013
R21 · FY2006 · AI · contact PI
ANALOGS OF HPMPA FOR TREATMENT OF SMALLPOX$1,391,660
R01 · FY2005 · AI
Nucleoside Phosphonate Analogs and HPV Positive Cancers$289,050
R01 · FY2005 · CA
Lung-Targeted Poxvirus Antivirals$288,800
R21 · FY2005 · AI
Nucleoside Phosphonate Analogs and HPV Positive Cancers$289,050
R01 · FY2004 · CA
PRODRUGS FOR THERAPY OF VIRAL RETINITIS IN AIDS$307,600
R01 · FY2002 · EY
PRODRUGS FOR THERAPY OF VIRAL RETINITIS IN AIDS$309,800
R01 · FY2001 · EY
OPTIMIZATION OF PRODRUGS FOR AZT/PFA RESISTANCE IN AIDS$340,543
R01 · FY2000 · AI
PRODRUGS FOR THERAPY OF VIRAL RETINITIS IN AIDS$311,400
R01 · FY2000 · EY
PRODRUGS FOR LOCAL THERAPY OF VIRAL RETINITIS$122,311
R01 · FY2000 · EY
OPTIMIZATION OF PRODRUGS FOR AZT/PFA RESISTANCE IN AIDS$20,300
R01 · FY2000 · AI